Catalyst
Slingshot members are tracking this event:
AveXis is set for its IPO of 4.25M shares of common stock at $19 - 21
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AVXS | Community voting in process | |||||
Additional Information
The clinical stage gene therapy firm develops treatments for rare and life-threatening genetic neurological disorders. Its lead product candidate is Phase 1-stage, Fast Track- and Orphan Drug-tagged AVXS-101 for the treatment spinal muscular atrophy (SMA) Type 1, caused by a defect in the SMN1 gene. SMA Type 1 is the leading genetic cause of infant mortality. It occurs in one in 10K live births.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 08, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Initial Public Offering
